Member LoginDividend CushionValue Trap
|
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
May 2, 2014
Valuentum's May Edition of Its Dividend Growth Newsletter!
The May edition of our Dividend Growth Newsletter is now available. Apr 17, 2014
Expect Abbott to Raise Its 2014 Outlook Soon
Abbott’s first-quarter results weren’t pristine, but the company’s better-than-expected first-quarter performance will eventually lead to an upwardly-revised full-year outlook, in our view. Feb 17, 2014
Deciphering Valuentum’s Dividend Lingo
Let’s examine how some investors are using the framework behind the Valuentum Dividend Cushion, if not the measure itself. Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space . Oct 20, 2013
Third-Quarter Industrial Earnings Support Exposure in Best Ideas Portfolio
A number of industrial firms’ calendar third-quarter earnings are out. Let’s take a look at how our Best Ideas portfolio is well-positioned to capture the strength of underlying trends. Oct 16, 2013
Abbott’s Expansion Slowed By Supplier Recall; Raises Dividend
Abbott’s results would have been even better were it not for a supplier recall in its ‘Nutrition’ business. Jul 29, 2013
AbbVie’s Humira Continues to Drive Strong Performance; Pipeline Advances
Humira continues to drive strong performance in the second quarter, while AbbVie's pipeline advances. Jul 18, 2013
Abbott's Nutrition Business Leads the Charge in Its Second Quarter
Abbott continues to be an international growth story. Let's dig into the firm's second-quarter numbers. Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015. The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
The June edition of the Best Ideas Newsletter is now available.